Neurocrine Biosciences (NBIX) FY2016 results: revenue $15 million, down 24.1% on the year
Neurocrine Biosciences Inc. (NBIX) reported revenue of $15 million for fiscal 2016, the year ended 31 December 2016, down 24.1% on the year before. Net income was -$141 million, and diluted earnings per share $-1.63. The figures are the company's own, from the 10-K it filed with the SEC on 14 February 2017.
Revenue
$15 million
-24.1% on the year
FY2009FY2016
Operating margin
-982.5%
-476.5% a year earlier
FY2009FY2016
Net income
-$141 million
FY2009FY2016
Diluted EPS
-$1.63
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
15.0
19.8
0.0
-24.1%
Cost of revenue
0.0
0.0
n/a
Gross profit
15.0
19.8
n/a
-24.1%
Gross margin
100.0%
100.0%
n/a
Research and development
94.3
81.5
46.4
+15.7%
Selling, general and administrative
68.1
32.5
n/a
+109.6%
Operating income
-147
-94.2
-64.4
Operating margin
-982.5%
-476.5%
n/a
Interest expense
0.0
0.0
n/a
Pre-tax income
-141
n/a
n/a
Income tax
0.0
0.0
0.0
Net income
-141
-88.9
-60.5
Net margin
-940.6%
-449.8%
n/a
Diluted EPS
-$1.63
-$1.05
-$0.81
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
-106
-38.0
-47.1
Capital expenditure
4.1
1.9
1.6
+112.4%
Free cash flow
-110
-39.9
-48.8
Free cash flow margin
-735.3%
-202.0%
n/a
Cash from investing
113
n/a
n/a
Cash from financing
2.4
n/a
n/a
Depreciation and amortisation
1.5
1.0
0.8
+44.0%
Share-based compensation
28.5
28.4
10.4
+0.3%
Diluted shares, weighted
87m
84m
75m
+2.6%
Shares outstanding at period end
87m
86m
76m
+0.7%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
315
424
209
-25.8%
Debt
0.0
0.0
0.0
Other liabilities
50.2
50.3
34.3
-0.2%
Total liabilities and equity
365
475
243
-23.1%
Fixed assets
6.3
3.4
2.5
+82.7%
Investments
268
387
200
-30.9%
Cash and equivalents
83.3
74.2
31.0
+12.2%
Receivables
0.0
n/a
n/a
Inventory
0.0
n/a
n/a
Other assets
8.0
9.7
9.2
-17.6%
Total assets
365
475
243
-23.1%
10-K for the year ended 31 December 2016, filed 14 February 2017: the filing.